$0.80
1.11% yesterday
Nasdaq, Jun 11, 10:17 pm CET
ISIN
IL0011814113
Symbol
PLRZ
Sector
Industry

Polyrizon Stock price

$0.80
-86.70 99.09% 1M
-237.25 99.66% 6M
-541.70 99.85% YTD
-386.70 99.79% 1Y
-386.70 99.79% 5Y
-386.70 99.79% 10Y
-386.70 99.79% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.01 1.11%
ISIN
IL0011814113
Symbol
PLRZ
Sector
Industry

Key metrics

Market capitalization $4.26m
Enterprise Value $1.71m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.63
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-1.65m
Free Cash Flow (TTM) Free Cash Flow $-1.15m
Cash position $2.55m
EPS (TTM) EPS $-0.74
Show more

Is Polyrizon a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

Financial data from Polyrizon

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 0.98 0.98
-
-
- Research and Development Expense 0.67 0.67
-
-
-1.53 -1.53
-
-
- Depreciation and Amortization 0.12 0.12
-
-
EBIT (Operating Income) EBIT -1.65 -1.65
-
-
Net Profit -2.23 -2.23
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Polyrizon directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Polyrizon Stock News

Neutral
GlobeNewsWire
20 days ago
Raanana, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced that it has received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), stating that based on its review of the Co...
Neutral
GlobeNewsWire
22 days ago
The Company demonstrated strong mucoadhesion and broad surface coverage in ex vivo nasal tissue models Raanana, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced compelling results from recent ex vivo studies demonstrating the muc...
Neutral
GlobeNewsWire
30 days ago
Raanana, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced the initiation of preclinical studies for intranasal Benzodiazepines (BZDs), a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, us...
More Polyrizon News

Company Profile

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Head office Israel
CEO Tomer Izraeli
Founded 2005
Website polyrizon-biotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today